Literature DB >> 19325136

The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.

Hye Jin You1, Tam How, Gerard C Blobe.   

Abstract

Transforming growth factor-beta (TGF-beta) increases or decreases nuclear factor kappa B (NFkappaB) signaling in a context-dependent manner through mechanisms that remain to be defined. The type III transforming growth factor-beta receptor (TbetaRIII) is a TGF-beta superfamily co-receptor with emerging roles in both mediating and regulating TGF-beta superfamily signaling. We have previously reported a novel interaction of TbetaRIII with the scaffolding protein, beta-arrestin2, which results in TbetaRIII internalization and downregulation of TGF-beta signaling. beta-arrestin2 also scaffolds interacting receptors with the mitogen-activated protein kinase and NFkappaB-signaling pathways. Here, we demonstrate that TbetaRIII, through its interaction with beta-arrestin2, negatively regulates NFkappaB signaling in MCF10A breast epithelial and MDA-MB-231 breast cancer cells. Increasing TbetaRIII expression reduced NFkappaB-mediated transcriptional activation and IkappaBalpha degradation, whereas a TbetaRIII mutant unable to interact with beta-arrestin2, TbetaRIII-T841A, had no effect. In a reciprocal manner, short hairpin RNA-mediated silencing of either TbetaRIII expression or beta-arrestin2 expression increased NFkappaB-mediated transcriptional activation and IkappaBalpha degradation. Functionally, TbetaRIII-mediated repression of NFkappaB signaling is important for TbetaRIII-mediated inhibition of breast cancer cell migration. These studies define a mechanism through which TbetaRIII regulates NFkappaB signaling and expand the roles of this TGF-beta superfamily co-receptor in regulating epithelial cell homeostasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19325136      PMCID: PMC2718069          DOI: 10.1093/carcin/bgp071

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  64 in total

Review 1.  Specificity, diversity, and regulation in TGF-beta superfamily signaling.

Authors:  E Piek; C H Heldin; P Ten Dijke
Journal:  FASEB J       Date:  1999-12       Impact factor: 5.191

Review 2.  Role of transforming growth factor beta in human disease.

Authors:  G C Blobe; W P Schiemann; H F Lodish
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

3.  Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.

Authors:  K A Lewis; P C Gray; A L Blount; L A MacConell; E Wiater; L M Bilezikjian; W Vale
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

4.  Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart.

Authors:  C B Brown; A S Boyer; R B Runyan; J V Barnett
Journal:  Science       Date:  1999-03-26       Impact factor: 47.728

5.  Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.

Authors:  Nadine Hempel; Tam How; Simon J Cooper; Tyler R Green; Mei Dong; John A Copland; Christopher G Wood; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2008-02-24       Impact factor: 4.944

6.  The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.

Authors:  Ryan S Turley; Elizabeth C Finger; Nadine Hempel; Tam How; Timothy A Fields; Gerard C Blobe
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells.

Authors:  Tracy L Criswell; Nancy Dumont; Joey V Barnett; Carlos L Arteaga
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

8.  Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation.

Authors:  Elizabeth C Finger; Nam Y Lee; Hye-jin You; Gerard C Blobe
Journal:  J Biol Chem       Date:  2008-10-08       Impact factor: 5.157

9.  Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC.

Authors:  Nam Y Lee; Bridgette Ray; Tam How; Gerard C Blobe
Journal:  J Biol Chem       Date:  2008-09-05       Impact factor: 5.157

10.  Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor.

Authors:  Kellye C Kirkbride; Todd A Townsend; Monique W Bruinsma; Joey V Barnett; Gerard C Blobe
Journal:  J Biol Chem       Date:  2008-01-09       Impact factor: 5.157

View more
  30 in total

Review 1.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

Review 2.  β-Arrestins: multifunctional signaling adaptors in type 2 diabetes.

Authors:  Xiaotao Feng; Wenjian Wang; Jibo Liu; Yi Liu
Journal:  Mol Biol Rep       Date:  2010-11-18       Impact factor: 2.316

3.  Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Authors:  S J Cooper; H Zou; S N Legrand; L A Marlow; C A von Roemeling; D C Radisky; K J Wu; N Hempel; V Margulis; H W Tun; G C Blobe; C G Wood; J A Copland
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

Review 4.  The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling.

Authors:  Yuri K Peterson; Louis M Luttrell
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

5.  miR-19a and miR-424 target TGFBR3 to promote epithelial-to-mesenchymal transition and migration of tongue squamous cell carcinoma cells.

Authors:  Duo Li; Ke Liu; Zhiyong Li; Jian Wang; Xiaofeng Wang
Journal:  Cell Adh Migr       Date:  2017-11-13       Impact factor: 3.405

6.  Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.

Authors:  Maree Bilandzic; Simon Chu; Yao Wang; Han L Tan; Peter J Fuller; Jock K Findlay; Kaye L Stenvers
Journal:  Mol Endocrinol       Date:  2013-01-15

7.  Type III TGFβ receptor and Src direct hyaluronan-mediated invasive cell motility.

Authors:  Patrick Allison; Daniella Espiritu; Joey V Barnett; Todd D Camenisch
Journal:  Cell Signal       Date:  2014-12-11       Impact factor: 4.315

8.  The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.

Authors:  Jason D Lee; Nadine Hempel; Nam Y Lee; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

Review 9.  Involvement of β-arrestins in cancer progression.

Authors:  Shanshan Hu; Di Wang; Jingjing Wu; Juan Jin; Wei Wei; Wuyi Sun
Journal:  Mol Biol Rep       Date:  2012-10-18       Impact factor: 2.316

10.  Common pathways regulate Type III TGFβ receptor-dependent cell invasion in epicardial and endocardial cells.

Authors:  Cynthia R Clark; Jamille Y Robinson; Nora S Sanchez; Todd A Townsend; Julian A Arrieta; W David Merryman; David Z Trykall; Harold E Olivey; Charles C Hong; Joey V Barnett
Journal:  Cell Signal       Date:  2016-03-10       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.